T2 Biosystems, which is developing diagnostic tests to screen for sepsis and impaired hemostasis, raised $57 million by offering 5.2 million shares at $11, well below the $15 to $17 range. T2 Biosystems plans to list on the NASDAQ under the symbol TTOO. Goldman Sachs and Morgan Stanley acted as joint bookrunners on the deal.
